Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04962347 · ClinicalTrials.gov registry record
Real World Study of COVID-19 in a Flyover Region
A clinical trial of Covid19, sponsored by Tulane University.
- Completed
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT04962347 is a study of Covid19 that has completed, run by Tulane University. The registered enrollment target is 1,800 participants, below the 2,683-participant average among 94 other Covid19 trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04962347, a study of Covid19, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Real world data are needed on remdesivir (RDV) efficacy in COVID-19, especially in the underserved populations of the United States (U.S.) Gulf Coast as initial clinical trials may not be representative of this population. Specifically, regions such as New Orleans are 60% African American, a much greater proportion of African Americans than initial RDV studies. The main hypothesis is that a real world data based study will provide specific information related to RDV efficacy in COVID-19 patients from underserved / underrepresented populations of the U.S. Gulf Coast. The main goal of this study is to provide population-centered information related on RDV related to indication (stage of disease), dosing, monitoring, efficacy and contraindications for future COVID-19 patients in this underserved region.
Conditions Studied
Study Locations (1)
Louisiana
- Tulane University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2022-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04962347
The ClinicalTrials.gov registry entry for NCT04962347 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,683-participant average among 94 other Covid19 trials with a reported enrollment target (33% lower). The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 0 interventions.
NCT04962347 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT04962347 about?
NCT04962347 is a clinical study titled "Real World Study of COVID-19 in a Flyover Region". Real world data are needed on remdesivir (RDV) efficacy in COVID-19, especially in the underserved populations of the United States (U.S.) Gulf Coast as initial clinical trials may not be representative of this population. Specifically, regions such as New Orleans are 60% African American, a much gr...
What is the current status of trial NCT04962347?
This trial is currently completed. The enrollment target is 1,800 participants. The study started on 2021-10-14. Estimated completion is 2022-10-18.
What conditions does trial NCT04962347 study?
This clinical trial studies the following conditions: Covid19.
Who is sponsoring clinical trial NCT04962347?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04962347 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
COVID-19 Vaccines International Pregnancy Exposure Registry
RECRUITING
-
COVID-19 Survivorship Registry
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Conversations You Want About Corona Virus Disease (COVID-19)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.